Literature DB >> 26887974

Systemic Inflammation Affects Human Osteocyte-Specific Protein and Cytokine Expression.

Janak L Pathak1,2,3, Astrid D Bakker4, Frank P Luyten5, Patrick Verschueren5, Willem F Lems6, Jenneke Klein-Nulend4, Nathalie Bravenboer7.   

Abstract

Bone remodeling can be disturbed in active rheumatoid arthritis (RA), possibly as a result of elevated levels of circulating inflammatory cytokines. Osteocyte-specific proteins and cytokines play a vital role in bone remodeling by orchestrating bone formation and/or bone resorption. Therefore, we aimed to investigate the effect of RA-serum or inflammatory cytokines on expression of human osteocyte-specific proteins and cytokines. Human trabecular bone chips were cultured with RA-serum or inflammatory cytokines for 7-days. Live-dead staining was performed to assess cell viability. Gene expression of osteocyte-specific proteins and cytokines was analyzed by qPCR. Immuno-staining was performed for osteocyte-specific markers. Approximately 60 % of the osteocytes on the bone chips were alive at day-7. Cells in or on the bone chips did express the gene for osteocyte markers SOST, FGF23, DMP1, and MEPE, and the cytokines IL-1β, IL-6, and TNFα at day 0 and 7. Active RA-serum treatment enhanced IL-1β, TNFα, SOST, and DKK1 gene expression. IL-1β treatment enhanced IL-1β, TNFα, IL-6, IL-8, FGF23, and SOST gene expression. TNFα treatment enhanced IL-1β, TNFα, IL-6, IL-8, and FGF23 gene expression. IL-8 treatment enhanced TNFα, IL-8, and FGF23 gene expression. A combination of IL-1β, IL-6, and TNFα treatment synergistically upregulated IL-1β, IL-6, and IL-8 gene expression, as well as enhanced TNFα, OPG, SOST, and FGF23, and inhibited DKK1 gene expression. In conclusion, gene expression of human osteocyte-specific proteins and cytokines was affected by RA-serum, and exogenous recombinant cytokines treatment suggesting that osteocytes could provide a new target to prevent systemic inflammation-induced bone loss in RA.

Entities:  

Keywords:  Bone loss; Chemokine; Cytokine; Inflammation; Osteocyte signaling; Rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 26887974     DOI: 10.1007/s00223-016-0116-8

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  26 in total

1.  A 3D, Dynamically Loaded Hydrogel Model of the Osteochondral Unit to Study Osteocyte Mechanobiology.

Authors:  Rachel L Wilmoth; Virginia L Ferguson; Stephanie J Bryant
Journal:  Adv Healthc Mater       Date:  2020-10-19       Impact factor: 9.933

Review 2.  The Osteocyte: New Insights.

Authors:  Alexander G Robling; Lynda F Bonewald
Journal:  Annu Rev Physiol       Date:  2020-02-10       Impact factor: 19.318

Review 3.  Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.

Authors:  Yongyong Yan; Liping Wang; Linhu Ge; Janak L Pathak
Journal:  Curr Osteoporos Rep       Date:  2020-02       Impact factor: 5.096

Review 4.  Cardiac actions of fibroblast growth factor 23.

Authors:  Christian Faul
Journal:  Bone       Date:  2016-10-07       Impact factor: 4.398

Review 5.  Pro-inflammatory Cytokines and Osteocytes.

Authors:  Miao Zhou; Shuyi Li; Janak L Pathak
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

Review 6.  Regulation of FGF23: Beyond Bone.

Authors:  Petra Simic; Jodie L Babitt
Journal:  Curr Osteoporos Rep       Date:  2021-11-10       Impact factor: 5.096

7.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.

Authors:  Saurav Singh; Alexander Grabner; Christopher Yanucil; Karla Schramm; Brian Czaya; Stefanie Krick; Mark J Czaja; Rene Bartz; Reimar Abraham; Giovana S Di Marco; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Kidney Int       Date:  2016-07-22       Impact factor: 10.612

8.  Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study.

Authors:  C-H Lin; C-K Chang; C-W Shih; H-Y Li; K-Y Chen; W-S Yang; K-S Tsai; C-Y Wang; S-R Shih
Journal:  Osteoporos Int       Date:  2019-08-05       Impact factor: 4.507

9.  The continuing problem of poor transparency of reporting and use of inappropriate methods for RT-qPCR.

Authors:  Stephen Bustin
Journal:  Biomol Detect Quantif       Date:  2017-05-23

Review 10.  Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review.

Authors:  Usama A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2017-02-27       Impact factor: 10.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.